(NASDAQ: UPB) Upstream Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.62%.
Upstream Bio's earnings in 2025 is -$122,774,000.On average, 8 Wall Street analysts forecast UPB's earnings for 2025 to be -$140,084,239, with the lowest UPB earnings forecast at -$147,222,737, and the highest UPB earnings forecast at -$137,879,465. On average, 7 Wall Street analysts forecast UPB's earnings for 2026 to be -$161,007,982, with the lowest UPB earnings forecast at -$204,417,182, and the highest UPB earnings forecast at -$146,390,543.
In 2027, UPB is forecast to generate -$163,736,931 in earnings, with the lowest earnings forecast at -$210,772,120 and the highest earnings forecast at -$134,475,034.